SOURCE: Provalis PLC

June 10, 2005 02:01 ET

Provalis PLC Announces Provalis appoints Peter Woodford as Non-Executive Director

Deeside, Flintshire, UK -- (MARKET WIRE) -- June 10, 2005 --

                                                      10 June 2005

Provalis plc

Provalis appoints Peter Woodford as Non-Executive Director

Provalis plc (LSE: PRO; NASDAQ: PVLS), the international medical diagnostics and
pharmaceuticals group, is pleased to announce that Peter Woodford, who has
extensive experience with Roche Diabetes Care, is appointed as a Non-Executive
Director of the Company with effect from 1 July 2005.

Frank Harding, Provalis Chairman, said;

"Peter brings with him more than 30 years experience in the international
healthcare industry with particular expertise in the diagnostics arena.  I know
he will make a significant contribution in helping Provalis to build the
commercial base and value creation in our innovative diagnostic point of care
platform in2it(TM)."

Peter Woodford, commented;

"I'm looking forward to joining Provalis at this time and am particularly
excited by the commercial potential of in2it(TM), the Group's flagship A1c
diabetes testing product.  With the US launch of in2it underway and the European
launches following later, together with the other tests in the pipeline, the
diagnostics business should now be set for growth in the year ahead."

Peter Woodford's early career included a variety of sales, marketing and general
management roles with several well-known companies in pharmaceuticals, medical
equipment and diagnostics. From 1987, Peter spent 15 years with Roche
Diagnostics/Boehringer Mannheim, serving as Managing Director of their UK
operations before moving into international roles in 1994. He served as Senior
Vice President, Roche Diabetes Care, responsible firstly for the Europe, Middle
East and Africa Region and latterly for Global Marketing, Strategy and Business
Development. He spent 8 years at the headquarters of Roche Diabetes Care in
Mannheim, Germany with a secondary base in Indianapolis, USA, leading all global
strategic and commercial activities for Roche Diabetes Care; a £1.2billion
business.

Peter left Roche in 2002 and has since been advising a number of companies and
investors in the diagnostics business. He is a non-executive director of BJS
Biotechnologies Ltd and a past vice chairman of the British In Vitro Diagnostics
Association.

                                 -------------

For further information:-

Provalis plc
    Dr Phil Gould, Chief Executive Officer                          01244 833463
    Mr Peter Bream, Finance Director                                01244 833552
College Hill
    Adrian Duffield/Corinna Dorward                           020 7457 2815/2803


Notes to Editors

Provalis plc (LSE: PRO; NASDAQ: PVLS) is an international healthcare group with
two operating businesses:-
     
-    Medical Diagnostics - develops medical diagnostic products for chronic 
     disease management for sale to world markets. The business' principal 
     products are in2it(TM) A1c and Glycosal(R), both diabetes diagnostic tests.
     
-    Pharmaceuticals - sells and markets its own, and third party, branded, 
     prescription medicines in the UK and Ireland to GPs and hospitals through 
     its regionally managed sales force. The business' principal product is 
     Diclomax(R), a medicine for use in the treatment of musculo-skeletal 
     disorders, and it also sells products in the areas of osteoporosis, 
     migraine and dermatology.

Visit Provalis' Revised Website at http://www.provalis.com

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of
1995: Statements in this announcement that relate to future plans, expectations,
events, performances and the like are forward-looking statements as defined in
the US Private Securities Litigation Reform Act of 1995. Actual results of
events could differ materially from those described in the forward-looking
statements due to a variety of factors.  Such factors include, among others: the
viability of the Group's products, which are at various stages of development;
the generation of sufficient operating cash flow by the Group's pharmaceutical
and medical diagnostic businesses to finance the ongoing development of these
businesses as well as the Group's research and development activities; the
success of the Group's research and development strategy and activities;
uncertainties related to future clinical trial results and the associated
regulatory process; the execution and success of collaborative agreements with
third parties; availability and level of reimbursement for the Group's products
from government health administration authorities or other third-party payors;
the rate of net cash utilisation within the Group and, hence, the Group's
possible need for additional capital in the short, medium and/or long term; the
Group's intellectual property position and the success of patent applications
for its products and technologies; the Group's dependence on key personnel;
general business and economic conditions; the impact of future laws, regulations
and policies; stock market trends in the Group's sector; and other factors
beyond the Group's control that may cause the Group's available capital
resources to be used more quickly than expected.  These and other factors that
could affect the Company's future results are more fully described in its
filings with the US Securities and Exchange Commission, in particular the latest
20-F filing, copies of which are available from the Company Secretary at the
Company's registered address.


                      This information is provided by RNS
            The company news service from the London Stock Exchange